EW (STOCKS)
Edwards Lifesciences Corp
$78.120000
+0.250000 (+0.32%)
Prev close: $77.870000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Bernard J. Zovighian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $45,348.86M
- Employees
- 15,800
- P/E (TTM)
- 43.03
- P/B (TTM)
- 4.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
20
Buy
12
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.58 | $0.64 | -0.0563 | -8.85% |
|
Sep 2025 (Q3)
|
$0.67 | $0.61 | +0.0588 | +9.62% |
|
Jun 2025 (Q2)
|
$0.67 | $0.64 | +0.0282 | +4.39% |
|
Mar 2025 (Q1)
|
$0.64 | $0.61 | +0.0253 | +4.12% |
Financial Statements
| Revenues | $6.07B |
| Benefits Costs and Expenses | $4.79B |
| Cost Of Revenue | $1.33B |
| Costs And Expenses | $4.79B |
| Gross Profit | $4.73B |
| Nonoperating Income/Loss | $8.70M |
| Operating Expenses | $3.47B |
| Selling, General, and Administrative Expenses | $2.09B |
| Research and Development | $1.08B |
| Other Operating Expenses | $304.80M |
| Operating Income/Loss | $1.26B |
| Income/Loss From Continuing Operations After Tax | $1.06B |
| Income/Loss From Continuing Operations Before Tax | $1.27B |
| Income/Loss From Discontinued Operations Net Of Tax | $13.40M |
| Income Tax Expense/Benefit | $216.90M |
| Income Tax Expense/Benefit, Current | $282.70M |
| Income Tax Expense/Benefit, Deferred | -$65.80M |
| Interest Income/Expense After Provision For Losses | -$20.40M |
| Interest Income/Expense Operating, Net | -$20.40M |
| Net Income/Loss | $1.07B |
| Net Income/Loss Attributable To Noncontrolling Interest | -$4.10M |
| Net Income/Loss Attributable To Parent | $1.07B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.07B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | $1.84 |
| Diluted Earnings Per Share | $1.83 |
| Basic Average Shares | 584,800,000 |
| Diluted Average Shares | 585,800,000 |
| Assets | $13.70B |
| Current Assets | $6.74B |
| Inventory | $1.13B |
| Prepaid Expenses | $135.00M |
| Other Current Assets | $5.48B |
| Noncurrent Assets | $6.96B |
| Fixed Assets | $1.81B |
| Intangible Assets | $1.13B |
| Other Non-current Assets | $4.02B |
| Liabilities | $3.36B |
| Current Liabilities | $1.81B |
| Accounts Payable | $227.50M |
| Wages | $467.50M |
| Other Current Liabilities | $1.12B |
| Noncurrent Liabilities | $1.55B |
| Equity | $10.34B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $10.34B |
| Liabilities And Equity | $13.70B |
| Net Cash Flow From Operating Activities | $1.60B |
| Net Cash Flow From Operating Activities, Continuing | $1.60B |
| Net Cash Flow From Investing Activities | -$712.90M |
| Net Cash Flow From Investing Activities, Continuing | -$712.90M |
| Net Cash Flow From Financing Activities | -$956.80M |
| Net Cash Flow From Financing Activities, Continuing | -$956.80M |
| Exchange Gains/Losses | -$44.80M |
| Net Cash Flow | -$119.30M |
| Net Cash Flow, Continuing | -$74.50M |
| Comprehensive Income/Loss | $1.08B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$4.10M |
| Comprehensive Income/Loss Attributable To Parent | $1.08B |
| Other Comprehensive Income/Loss | $6.20M |
| Other Comprehensive Income/Loss Attributable To Parent | $6.20M |